Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: May 20, 2026

Real-time Quaking-induced Conversion Assay for Detection of CWD Prions in Fecal Material
09:50

Real-time Quaking-induced Conversion Assay for Detection of CWD Prions in Fecal Material

Published on: September 29, 2017

Prion inhibition with multivalent PrPSc binding compounds.

Charles E Mays1, Shaon Joy, Lei Li

  • 1Centre for Prions and Protein Folding Diseases, University of Alberta, Edmonton, Alberta, Canada.

Biomaterials
|July 4, 2012
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A model-based prion vaccine protects a transgenic mouse line carrying a Gerstmann-Sträussler-Scheinker disease mutation.

Acta neuropathologica·2026
Same author

A cationic single-chain bolalipid forms stable vesicles with distinct interfacial behavior.

Biophysical journal·2026
Same author

Liposomal Delivery of Pyronaridine as a Repurposed Inhibitor of ERCC1/XPF for the Sensitization of Colorectal Cancer Cells to Platinum Chemotherapeutics.

Molecular pharmaceutics·2025
Same author

Synthesis and Evaluation of Fluorinated Peptidomimetics Enabling the Development of <sup>18</sup>F-Labeled Radioligands Targeting Muscarinic Acetylcholine Receptor Subtype M3.

ChemMedChem·2025
Same author

A chemoproteomic strategy for identifying protein covalent binding targets of clozapine: An approach for advancing clozapine toxicity research.

Toxicology letters·2025
Same author

Expression of progerin enhances disease-related endpoints in a tau seeding reporter cell system.

GeroScience·2025
Same journal

A sonosensitizing hydrogel with tumour-confined stability for intrinsically targeted sonodynamic therapy.

Biomaterials·2026
Same journal

Multidimensional intestinal barrier repair strategies for alleviating inflammatory bowel disease and gut-liver axis-associated metabolic liver disease.

Biomaterials·2026
Same journal

A dual-twisted molecular strategy achieves dramatic quantum-yield enhancement in NIR-II AIEgen for high-performance bioimaging.

Biomaterials·2026
Same journal

An oxygen-glucose co-releasing platform fostering dental pulp regeneration by driving metabolic recovery of stem cells.

Biomaterials·2026
Same journal

Prodrug-decorated 2D hafnium sulfide nanoplatelets as "amplify-and-arrest" platforms for radiosensitization and homologous recombinant inhibition in solid tumor.

Biomaterials·2026
Same journal

In-situ cascade assembled peptide-drug conjugate for the treatment of bladder cancer by enhancing membrane-entry and lysosome destabilization.

Biomaterials·2026
See all related articles

Researchers developed novel multivalent compounds with enhanced antiprion activity against prion diseases. These compounds, based on quinacrine derivatives, show promise for future prion disease therapeutics.

Area of Science:

  • Neuroscience
  • Medicinal Chemistry
  • Biochemistry

Background:

  • Prion diseases are fatal neurodegenerative disorders caused by misfolded prion proteins (PrPSc).
  • Quinacrine and related compounds exhibit antiprion activity by targeting PrPSc assemblies.

Purpose of the Study:

  • To enhance antiprion activity by creating multivalent compounds with multiple quinacrine-derived moieties.
  • To investigate the structure-activity relationship of these novel compounds.

Main Methods:

  • Synthesized multivalent compounds by attaching chloroquinoline or acridine units to various scaffolds (trimesic acid, tetraphenylporphyrin tetracarboxylic acid).
  • Assessed antiprion activity in infected cultured cells and evaluated toxicity.
  • Analyzed the influence of linker properties (length, polarity, rigidity) on activity.

More Related Videos

Delivery of Therapeutic siRNA to the CNS Using Cationic and Anionic Liposomes
10:33

Delivery of Therapeutic siRNA to the CNS Using Cationic and Anionic Liposomes

Published on: July 23, 2016

Protein Misfolding Cyclic Amplification of Prions
10:12

Protein Misfolding Cyclic Amplification of Prions

Published on: November 7, 2012

Related Experiment Videos

Last Updated: May 20, 2026

Real-time Quaking-induced Conversion Assay for Detection of CWD Prions in Fecal Material
09:50

Real-time Quaking-induced Conversion Assay for Detection of CWD Prions in Fecal Material

Published on: September 29, 2017

Delivery of Therapeutic siRNA to the CNS Using Cationic and Anionic Liposomes
10:33

Delivery of Therapeutic siRNA to the CNS Using Cationic and Anionic Liposomes

Published on: July 23, 2016

Protein Misfolding Cyclic Amplification of Prions
10:12

Protein Misfolding Cyclic Amplification of Prions

Published on: November 7, 2012

Main Results:

  • Trimesic acid-based compounds showed potent sub-micromolar IC50 values and improved toxicity profiles compared to quinacrine.
  • Tetraphenylporphyrin tetracarboxylic acid scaffolds showed some reduction in PrPSc.
  • Antiprion activity varied with linker characteristics and was modulated by host cell and prion strain.
  • Some compounds unexpectedly increased PrPSc levels.

Conclusions:

  • Multivalent quinacrine derivatives demonstrate significant antiprion potential, offering a promising foundation for drug development.
  • The study highlights the importance of scaffold and linker design in optimizing antiprion efficacy and safety.
  • Further investigation into both inhibitory and enhancing effects is warranted for understanding prion biology.